KR920702383A - 치료제의 방출을 조절하는데 유용한 생부식성 중합체 - Google Patents

치료제의 방출을 조절하는데 유용한 생부식성 중합체

Info

Publication number
KR920702383A
KR920702383A KR1019920700460A KR920700460A KR920702383A KR 920702383 A KR920702383 A KR 920702383A KR 1019920700460 A KR1019920700460 A KR 1019920700460A KR 920700460 A KR920700460 A KR 920700460A KR 920702383 A KR920702383 A KR 920702383A
Authority
KR
South Korea
Prior art keywords
polymer
hydrogen
carbon atoms
composition
cycloalkylene
Prior art date
Application number
KR1019920700460A
Other languages
English (en)
Inventor
스티브 와이 더블유. 엔지
조지 헬로
Original Assignee
원본미기재
파마슈티컬 딜리버리 시스템즈 인코오퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/400,532 external-priority patent/US5030457A/en
Application filed by 원본미기재, 파마슈티컬 딜리버리 시스템즈 인코오퍼레이티드 filed Critical 원본미기재
Publication of KR920702383A publication Critical patent/KR920702383A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/009—Materials resorbable by the body
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/43—Hormones, e.g. dexamethasone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Abstract

내용 없음

Description

치료제의 방출을 조절하는데 유용한 생부식성 중합체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 산성 부형제가 본 발명의 오르토-에스테르-기제 조성물의 생부식의 속도에 미치는 영향을 나타내는 그래프이다.

Claims (24)

  1. 생부식성 중합체를 제조하는 방법에 있어서, 일반식
    의 모노머성 오르토에스테르를 일반식
    의 트리올과 반응시켜 하기 구조
    를 가진 머(mer) 단위로 이루어지는 비경질의, 생부식성 오르토에스테르 중합체를 형성하는 것으로 이루어지는 것을 특징으로 하는 방법.
    상기 식에서, R은 수소 또는 탄소수가 1내지 10인 알킬이고 R'는 저급 알킬이고 A는 탄소수가 적어도 5인 알킬렌과 서클로알킬렌 및 탄소수가 적어도 5인 옥시알킬렌과 시클로옥시알킬렌으로 부터 선택된다.
  2. 제1항에 있어서, R은 수소 또는 저급 알킬인 것을 특징으로 하는 방법.
  3. 제1항에 있어서, A는 탄소수가 약 5내지 약20인 알킬렌인 것을 특징으로 하는 방법.
  4. 제1항에 있어서, A는 탄소수가 약 5내지 20인 시클로알킬렌 부분인 것을 특징으로 하는 방법.
  5. 제1항에 있어서, A는 탄소수가 약 5내지 20인 시클로옥시알킬렌 부분인 것을 특징으로 하는 방법.
  6. 제5항에 있어서, 상기한 트리올은 당 잔기인 것을 특징으로 하는 방법.
  7. 제1항에 있어서, A는 일반식
    을 가지는 것을 특징으로 하는 방법.
    상기식에서, x는 0또는 1이고, y는 2이상이고 R"은 수소와 저급알킬로 이루어지는 군으로부터 독립적으로 선택된다.
  8. 제7항에 있어서, x는 0이고 y는 4이고 R"은 각각 수소인 것을 특징으로 하는 방법.
  9. 제1항에 있어서, 최종 중합체에서 머 단위의 수는 약 5내지 1000의 범위에 있는 것을 특징으로 하는 방법.
  10. 하기 구조의 머 단위를 함유하는 것을 특징으로 하는 중합체.
    상기 식에서 R은 수소 또는 탄소수가 1내지 10이 알킬이고 A는 탄소수가 적어도 5인 시클로알킬렌, 탄소수가 적어도 5인 시클로옥시알킬렌 및 하기 구조
    를 가진 알킬렌으로 이루어진는 군으로부터 선택되고, 여기서 x는 0또는 1이고, y는 3이상이고 R"은 수소와 저급알킬로 이루어지는 군으로부터 독립적으로 선택된다.
  11. 제10항에 있어서, A는 탄소수가 약 5내지 20인 시클로알킬렌인 것을 특징으로 하는 중합체.
  12. 제11항에 있어서, A는 탄소수가 약 5내지 10인 시클로알킬렌인 것을 특징으로 하는 중합체.
  13. 제10항에 있어서, A는 시클로알킬렌이고 펜타푸라노스 고리로 이루어지는 것을 특징으로 하는 중합체.
  14. 제10항에 있어서, R은 수소 또는 저급 알킬인 것을 특징으로 하는 중합체.
  15. 제10항에 있어서, R은 수소 또는 저급 알킬인 것을 특징으로 하는 중합체.
  16. 제10항에 있어서, 분자량이 적어도 약 500인 것을 특징으로 하는 중합체.
  17. 제10항에 있어서, 분자량이 적어도 약 2,000인 것을 특징으로 하는 중합체.
  18. 제약학적으로 허용되는 담체와 함께 담체중에 분산된 제10항의 중합체로 이루어지는 치료에 효과적인 양의 치료제로 이루어지는 것을 특징으로 하는 생부식성 제약학적 조성물.
  19. 제18항에 있어서, 첨가된 산으로 더 이루어지는 것을 특징으로 하는 조성물.
  20. 제18항에 있어서, 연고형태인 것을 특징으로 하는 조성물.
  21. 제18항에 있어서, 크림 형태인 것을 특징으로 하는 조성물.
  22. 제18항에 있어서, 고체 이식제 형태인 것을 특징으로 하는 조성물.
  23. 제18항에 있어서, 치료제는 단백질 함유 약제인 것을 특징으로 하는 조성물.
  24. 제18항에 있어서, 치료제는 항균제, 항생제, 항염제, 항고혈합제, 항바이러스제 및 부신 코르티코스테로이드로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920700460A 1989-08-28 1990-08-23 치료제의 방출을 조절하는데 유용한 생부식성 중합체 KR920702383A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US400532 1989-08-28
US07/400,532 US5030457A (en) 1989-08-28 1989-08-28 Bioerodible polymers useful for the controlled release of therapeutic agents
US55664590A 1990-07-20 1990-07-20
US556645 1990-07-20
US56843390A 1990-08-16 1990-08-16
US568433 1990-08-16
PCT/US1990/004804 WO1991003510A1 (en) 1989-08-28 1990-08-23 Bioerodible polymers useful for the controlled release of therapeutic agents

Publications (1)

Publication Number Publication Date
KR920702383A true KR920702383A (ko) 1992-09-03

Family

ID=27410406

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920700460A KR920702383A (ko) 1989-08-28 1990-08-23 치료제의 방출을 조절하는데 유용한 생부식성 중합체

Country Status (8)

Country Link
US (2) US5336505A (ko)
EP (1) EP0489843A4 (ko)
JP (1) JPH05502465A (ko)
KR (1) KR920702383A (ko)
AU (1) AU6402490A (ko)
FI (1) FI920856A0 (ko)
LV (1) LV10871B (ko)
WO (1) WO1991003510A1 (ko)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461140A (en) * 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5589510A (en) * 1994-06-02 1996-12-31 Fuji Immunopharmaceuticals Corp. Method for inhibiting retroviral infection by administering a naphthalenesulfonic acid compound
BR9706960A (pt) * 1996-01-05 1999-12-28 Advanced Polymer Systems Inc Polìmeros com estado fìsico e condição de bioerosão controlados
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US5817328A (en) * 1996-01-17 1998-10-06 Cambridge Scientific, Inc. Material for buffered resorbable internal fixation devices and method for making same
DE69716586T2 (de) 1996-03-05 2003-07-17 Robert Gurny Gepufferte orthoesterpolymere enthaltende arzneimittel
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
EP1225172B1 (en) * 1999-09-17 2004-07-21 Kansai Paint Co., Ltd. Polyorthoester and curable composition containing the same
DE60034368T2 (de) 1999-12-28 2008-01-03 Kimberly-Clark Worldwide, Inc., Neenah Verwendungs-abhängiges indikatorsystem für absorbierende artikel
DE60038980D1 (de) 1999-12-28 2008-07-03 Kimberly Clark Co Antimikrobielles wischtuch mit kontrollierter abgabe für harte oberflächen
ATE377048T1 (de) 2000-09-06 2007-11-15 Ap Pharma Inc Abbaubare polyacetal-polymere
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US20030152630A1 (en) * 2001-05-11 2003-08-14 Ng Steven Y. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6590059B2 (en) * 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
US20110092677A1 (en) * 2001-08-30 2011-04-21 Biorexis Technology, Inc. Modified transferin-antibody fusion proteins
US7435722B2 (en) * 2001-08-31 2008-10-14 University Of Southern California Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
CA2458821C (en) * 2001-08-31 2012-01-10 University Of Southern California Use of non-toxic crosslinking agents to inhibit mechanical degradation of collagenous tissues
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US6993846B2 (en) * 2002-05-08 2006-02-07 Eveready Battery Company, Inc. Lubricating strip
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
WO2004035754A2 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US7045589B2 (en) * 2002-11-15 2006-05-16 A.P. Pharma, Inc. Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them
US7090433B2 (en) * 2003-10-07 2006-08-15 Steve Searby Underground cable laying apparatus
SI2409707T1 (sl) 2004-04-15 2015-07-31 Alkermes Pharma Ireland Limited Naprava s podaljšanim sproščanjem na osnovi polimerov
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8252776B2 (en) * 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US9192615B2 (en) 2008-08-06 2015-11-24 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US7875697B2 (en) 2006-06-29 2011-01-25 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
DK2359808T3 (da) 2006-08-09 2013-08-05 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelaggregater
US7740699B2 (en) * 2006-10-05 2010-06-22 E.I. Du Pont De Nemours And Company Orthoformate-protected polyols
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
KR20140032505A (ko) * 2006-11-09 2014-03-14 알콘 리서치, 리미티드 약물 전달용 수불용성 폴리머 매트릭스
AU2008231093A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8956642B2 (en) * 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8475823B2 (en) * 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
JP2011513337A (ja) * 2008-04-18 2011-04-28 ウォーソー・オーソペディック・インコーポレーテッド 椎間板ヘルニアを治療するための方法および組成物
US20100240852A1 (en) * 2009-03-23 2010-09-23 Medtronic, Inc. Heteroatom-containing polymers and metathesis polymerization methods for making same
EP2464389A2 (en) 2009-08-06 2012-06-20 Koninklijke Philips Electronics N.V. Oncology therapies employing radioactive seeds
ES2650667T3 (es) 2009-09-28 2018-01-19 Intarcia Therapeutics, Inc Rápido establecimiento y/o terminación de la administración sustancial de fármaco en estado estacionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4186185A (en) * 1976-04-08 1980-01-29 Alza Corporation Compositions comprising arylene substituted poly(orthoesters) containing useful agents
US4066747A (en) * 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4122158A (en) * 1976-09-23 1978-10-24 Alza Corporation Topical therapeutic preparations
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4405798A (en) * 1981-03-30 1983-09-20 Celanese Corporation Acrylate and methacrylate monoesters of pentaerythritol and pentaerythritol orthoesters and polymers and copolymers derived therefrom
US4549010A (en) * 1984-06-27 1985-10-22 Merck & Co., Inc. Bioerodible poly(ortho ester) thermoplastic elastomer from diketene diacetal
CA1276556C (en) * 1985-07-08 1990-11-20 Kenneth J. Himmelstein Organic acid as catalysts for the erosion of polymers
US4814173A (en) * 1987-09-08 1989-03-21 Warner-Lambert Company Silicone elastomer transdermal matrix system
US5030457A (en) * 1989-08-28 1991-07-09 Pharmaceutical Delivery Systems, Inc. Bioerodible polymers useful for the controlled release of therapeutic agents

Also Published As

Publication number Publication date
FI920856A0 (fi) 1992-02-26
EP0489843A1 (en) 1992-06-17
AU6402490A (en) 1991-04-08
US5336505A (en) 1994-08-09
EP0489843A4 (en) 1992-08-12
JPH05502465A (ja) 1993-04-28
LV10871B (en) 1996-06-20
WO1991003510A1 (en) 1991-03-21
LV10871A (lv) 1995-10-20
US5824343A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
KR920702383A (ko) 치료제의 방출을 조절하는데 유용한 생부식성 중합체
US4349538A (en) Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
KR960700062A (ko) 산성 pH에서의 안정성을 개선시키기 위해 변형된 올리고누클레오티드(OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACIC pH)
FR2382893A1 (fr) Composition pharmaceutique a base de cholestyramine
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
KR910018398A (ko) 3당류 유니트(unit)를 함유하는 탄수화물 유도체
FR2684385B1 (fr) Heparosanes-n,o-sulfates de haute masse moleculaire, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
UA79430C2 (en) Method for the stepwise attachment of polyethylene glycol to polypeptide
KR940703806A (ko) 20-메틸-치환된 비타민 D 유도체 (20-Methyl-Substituted Vitamin D Derivatives)
ES8802206A1 (es) Procedimiento para la preparacion de microparticulas que permiten la liberacion prolongada de una substancia biologicameente activa.
BR9811585A (pt) Agonistas de vasopressinas tricìclicas
JPS56128767A (en) Substituted imidazole derivative, its manufacture and medicine as effective component
ATE38834T1 (de) 5-substituierte 1,2,4-oxadiazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JPH08501317A (ja) 抗菌性インターフェロン誘発性医薬品
MY120318A (en) Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses.
IL128317A (en) A preparation containing mopirocin and chlorhexidine
FR2428050A1 (fr) Oligomeres de composes du type muramyl-peptide et medicaments les contenant
KR900003105A (ko) N-2,3-부타디엔일 트리- 및 테트라아미노알칸 유도체
HUP9900767A2 (hu) Pirrolidinil-hidroxámsav-származékok és intermedierjeik, előállításuk és a vegyületeket tartalmazó gyógyászati készítmények
KR910002437A (ko) 항염증성 조성물, 항알레르기성 조성물 또는 이들 혼합성질의 조성물
KR900018160A (ko) 폴리스티렌 중합체
MC2280A1 (fr) Derives de galactomannanes utilisables pour le revetement ou l'enrobage de substances actives de medicaments
KR880000432A (ko) 4(3H)-옥소-5,6,7,8-테트라히드로피리도-2,3-d 피리미딘 유도체
JP2688057B2 (ja) 抗腺がん剤
KR970701545A (ko) 퀴놀린-3-카르복사미드 화합물의 새로운 용도(new use of quinoline-3-carboxamide compounds)

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid